C

China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062

Watchlist Manager
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Watchlist
Price: 21.81 CNY 0.37% Market Closed
Market Cap: 22.4B CNY
Have any thoughts about
China Resources Double-Crane Pharmaceutical Co Ltd?
Write Note

China Resources Double-Crane Pharmaceutical Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

China Resources Double-Crane Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
C
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Net Income (Common)
ÂĄ1.6B
CAGR 3-Years
15%
CAGR 5-Years
9%
CAGR 10-Years
7%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
ÂĄ3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Income (Common)
ÂĄ3B
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
22%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
ÂĄ5.4B
CAGR 3-Years
-5%
CAGR 5-Years
4%
CAGR 10-Years
15%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
ÂĄ4.5B
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Income (Common)
-ÂĄ780.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is China Resources Double-Crane Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
1.6B CNY

Based on the financial report for Jun 30, 2024, China Resources Double-Crane Pharmaceutical Co Ltd's Net Income (Common) amounts to 1.6B CNY.

What is China Resources Double-Crane Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
7%

Over the last year, the Net Income (Common) growth was 33%. The average annual Net Income (Common) growth rates for China Resources Double-Crane Pharmaceutical Co Ltd have been 15% over the past three years , 9% over the past five years , and 7% over the past ten years .

Back to Top